美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Invesco Nasdaq Biotechnology ETF

33.43

-0.8148-2.38%

盘后：33.440.0066+0.02%19:30 EDT

成交量：4.33万

成交额：145.21万

市值：1.08亿

市盈率：- -

高：34.02

开：34.02

低：33.43

收：34.25

52周最高：36.84

52周最低：25.00

股本：322.00万

流通股本：322.00万

量比：0.99

换手率：1.34%

股息：0.39

股息率：1.17%

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

美股异动 | 美国临床阶段生物制药公司Retension Pharmaceuticals(RTSN.US)登陆美股市场开盘后股价跌超10%

联环药业创新药项目取得新进展，能否持续提振公司业绩？

加皇银行上调安进目标价至430美元

中金公司：有色、创新药等多领域三季报有望延续高增长

东方财富网

【券商聚焦】中泰国际：多家药企将公布重要数据推荐创新药与CXO龙头

阿斯利康两款重磅ADC药物在华获批新适应证；恒瑞医药第二款自主研发的创新药向欧盟递交上市申请丨医药早参

每日经济新闻

XORTX概述了预计向加拿大卫生部提交的XRX-026治疗痛风临床试验申请。

三季报“窗口期”将至，机构看好AI、创新药等领域，投资者该如何关注？丨经济周刊·理财

东方财富网

星巴克曾洽谈收购Chipotle 拟打造餐饮业重磅并购交易

环球市场播报

乐普医疗(300003.SZ)子公司MWN117注射液获得美国FDA药物临床试验批准

核心产品海外三期研究失败艾力斯20cm跌停还带崩了创新药板块？

核心产品海外三期研究失败艾力斯20cm跌停还带崩了创新药板块？

东方财富网

众生药业(002317.SZ)：一类创新药RAY1225注射液减重III期临床试验获得顶线分析数据结果

天坛生物(600161.SH)下属企业获得人凝血因子Ⅸ临床试验总结报告

Truist上调安进目标价至380美元

天坛生物：成都蓉生人凝血因子Ⅸ获Ⅲ期临床试验总结报告

小摩上调吉利德科学目标价至170美元

翰宇药业：HY3003注射液临床试验申请获FDA受理

核心产品海外关键Ⅲ期临床未达主要终点，400亿创新药企跌停

东方财富网

韩国1至9月生物制药出口额创纪录，达66亿美元

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/IBBQ/news?page=3"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBBQ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","market":"US","secType":"STK","nameCN":"Invesco Nasdaq Biotechnology ETF","latestPrice":33.4334,"timestamp":1791921600000,"preClose":34.2482,"halted":0,"volume":43277,"hourTrading":{"tag":"盘后","latestPrice":33.44,"preClose":33.4334,"latestTime":"19:30 EDT","volume":143,"amount":4820.2502,"timestamp":1791934204007,"change":0.0066,"changeRate":0.000197,"amplitude":0},"delay":0,"changeRate":-0.02379103135347254,"floatShares":3220001,"shares":3220001,"eps":0,"marketStatus":"未开盘","change":-0.8148,"latestTime":"10-13 16:00:00 EDT","open":34.02,"high":34.02,"low":33.4334,"amount":1452145.02082,"amplitude":0.017128,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1791964800000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":34.2482,"sharesOutstanding":2520001,"nav":34.23493,"aum":110578858.13493,"dividendRate":0.011701,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":33.44,"preClose":33.4334,"latestTime":"19:30 EDT","volume":143,"amount":4820.2502,"timestamp":1791934204007,"change":0.0066,"changeRate":0.000197,"amplitude":0},"volumeRatio":0.993512,"impliedVol":0.1579,"impliedVolPercentile":0.6653},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","floatShares":3220001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.993512,"shares":3220001,"dividePrice":0.3912,"high":34.02,"amplitude":0.017128,"preClose":34.2482,"low":33.4334,"week52Low":25,"pbRate":"--","week52High":36.84,"institutionHeld":0,"latestPrice":33.4334,"eps":0,"divideRate":0.011701,"volume":43277,"delay":0,"ttmEps":0,"open":34.02,"prevYearClose":28.3962,"prevWeekClose":34.62,"prevMonthClose":35.14,"prevQuarterClose":35.14,"fiveDayClose":33.9,"twentyDayClose":34.25,"sixtyDayClose":32.04},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBBQ\",params:#limit:5,,,undefined,":[{"date":"2026-09-21","symbol":"IBBQ","amount":0.23037,"announcedDate":"2026-09-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-21","defaultRemindTime":1789997400000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-25","payableDate":"2026-09-21","currency":"USD","dateTimestamp":1789963200000,"payDate":"2026-09-25"},{"date":"2026-06-22","symbol":"IBBQ","amount":0.03422,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-03-23","symbol":"IBBQ","amount":0.03609,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-12-22","symbol":"IBBQ","amount":0.0906,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2025-09-22","symbol":"IBBQ","amount":0.09576,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBBQ\",market:\"US\",,,undefined,":[{"executeDate":"2021-09-20","recordDate":"2021-09-21","paymentDate":"2021-09-30","value":0.04324,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-31","value":0.10511,"currency":"USD"},{"executeDate":"2022-03-21","recordDate":"2022-03-22","paymentDate":"2022-03-31","value":0.03778,"currency":"USD"},{"executeDate":"2022-06-21","recordDate":"2022-06-22","paymentDate":"2022-06-30","value":0.04264,"currency":"USD"},{"executeDate":"2022-09-19","recordDate":"2022-09-20","paymentDate":"2022-09-23","value":0.03769,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBBQ\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBBQ\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2674865591","title":"美股异动 | 美国临床阶段生物制药公司Retension Pharmaceuticals(RTSN.US)登陆美股市场 开盘后股价跌超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674865591","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674865591?lang=zh_cn&edition=fundamental","pubTime":"2026-10-10 00:21","pubTimestamp":1791562908,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周五，Retension Pharmaceuticals(RTSN.US)登陆美股市场，截至发稿，该股跌超10%，报10.77美元。IPO价格为12美元。Retension Pharmaceuticals是一家美国临床阶段生物制药公司，专注于开发治疗高血压及其他心血管疾病的创新药物。公司的核心在研药物RTN-001是一款新一代磷酸二酯酶5(PDE5)抑制剂，主要针对血压未得到有效控制及难治性高血压患者，目前正开展IIb期临床试验。该药物通过增强血管中的一氧化氮信号传导，帮助血管舒张、降低血压，其全球独家开发许可来自法国制药巨头赛诺菲安万特(SNY.US)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1505512.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BBP","BK1610","03069","MRNX","RTSN","IBBQ","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674421834","title":"联环药业创新药项目取得新进展，能否持续提振公司业绩？","url":"https://stock-news.laohu8.com/highlight/detail?id=2674421834","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674421834?lang=zh_cn&edition=fundamental","pubTime":"2026-10-09 15:40","pubTimestamp":1791531601,"startTime":"0","endTime":"0","summary":"联环药业创新药项目取得新进展，能否提振公司业绩？近期，联环药业1类创新药LH-1801正式提交申报材料，进入CDE受理等待阶段，其创新转型之路取得阶段性成果。联环药业此前在公告中坦承，预计该项目在未来相当一段时间内不会对公司的营业收入和经营业绩产生重大影响。在联环药业披露LH-1801项目进展后，公司股票于10月8日强势涨停，10月9日开盘后继续上冲，股价走势直观反映出资本市场对公司发展前景的乐观预期。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202610/09/20261009838314.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202610/09/20261009838314.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20261009/32391452.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1574","IBBQ","06978","600513","159992","BK0239","LNGR","BK1161","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674833455","title":"加皇银行上调安进目标价至430美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674833455","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674833455?lang=zh_cn&edition=fundamental","pubTime":"2026-10-09 13:49","pubTimestamp":1791524960,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BBH","IE0002141913.USD","LU1057294990.SGD","LU0889565916.HKD","TBXU","BK4588","SG9999001440.SGD","LU1983299246.USD","LU0868494617.USD","PJP","PBE","BK4139","IE00BFTCPJ56.SGD","LU2112291526.USD","IE00BJT1NW94.SGD","BK4566","UUP","LU0122379950.USD","BK4533","LU1061106388.HKD","IBB","LU1023059063.AUD","LU2089984988.USD","BIB","AMGN","LU0058720904.USD","BK4534","BK4581","LU0320765992.SGD","IBBQ","LU2242646821.SGD","LU2468319806.SGD","LU1571399168.USD","IE0009355771.USD","LU0289739699.SGD","BK4585","BK4599","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU0109394709.USD","IE00BJJMRZ35.SGD","UDN","LU2242652126.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674884452","title":"中金公司：有色、创新药等多领域三季报有望延续高增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2674884452","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674884452?lang=zh_cn&edition=fundamental","pubTime":"2026-10-09 09:14","pubTimestamp":1791508445,"startTime":"0","endTime":"0","summary":"新华财经上海10月9日电中金公司研报分析认为，三季报A股整体盈利增速或环比回落，结构分化延续，上游能源原材料及TMT领域有望延续较高增长。结合行业分析师自下而上的观察视角，部分有色金属、受益于AI高景气与海外需求的科技硬件、创新药、CXO、水电核电、工程机械、液冷、集运油运、白酒、免税、旅游、游戏等领域三季报盈利增速有望较中报继续改善。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://stock.eastmoney.com/news/11215,202610093890505926.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.eastmoney.com/news/11215,202610093890505926.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["LU0359201885.HKD","159876","LU2663582299.SGD","LU2351347302.SGD","LNGR","LU0259732245.USD","LU1508157978.USD","BK1147","MEDX","159992","LU2929501877.USD","SG9999002828.SGD","03908","LU0359202008.SGD","LU1023057109.AUD","601995","BK1516","LU2187417386.USD","LU1781817850.SGD","LU0359201612.USD","BK1161","BK0276","BK1574","BK1564","LU1580142542.USD","06978","IBBQ","BK1501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674892318","title":"【券商聚焦】中泰国际：多家药企将公布重要数据 推荐创新药与CXO龙头","url":"https://stock-news.laohu8.com/highlight/detail?id=2674892318","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674892318?lang=zh_cn&edition=fundamental","pubTime":"2026-10-09 08:38","pubTimestamp":1791506310,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中泰国际表示，多家创新药企业将于10月下旬ESMO公布重要临床数据。ESMO是欧洲最具盛名和影响力的肿瘤学会议，LBA是最高级别的研究成果展示，因此ESMO公布的LBA在医药行业广受关注。中国企业入选的LBA中，有四项入选最高级别的主席研讨会。该机构认为，以上情况表明中国创新药研发能力在海外广受认可，因此创新药板块值得继续关注。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993342","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1688375341.USD","LU1242518931.SGD","LU0327786744.USD","LU0348783233.USD","LU2125910500.SGD","LU0314109678.HKD","LU0561508036.HKD","06978","LU0307460666.USD","LU1831875114.USD","LU0149534421.HKD","02359","09926","KURE","LU1008478684.HKD","LU0067412154.USD","LU0708995153.HKD","IBBQ","LU1960683339.HKD","LU0572944931.SGD","MEDX","02269","KCE","SG9999002463.SGD","BK1191","06160","WX","LU2399975544.HKD","01801","LU0029874905.USD","159992","02268","BK1500","LU0823426308.USD","BK1521","06821","IE00B5MMRT66.SGD","LU2488822045.USD","01093","LU0348827113.USD","LU2097828557.USD","LNGR","CXO","LU0320764599.SGD","00013","01177","IE00BZ08YR35.GBP","LU0348767384.USD","IE0008369823.USD","LU2097828714.EUR"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2674885482","title":"阿斯利康两款重磅ADC药物在华获批新适应证；恒瑞医药第二款自主研发的创新药向欧盟递交上市申请丨医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2674885482","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674885482?lang=zh_cn&edition=fundamental","pubTime":"2026-10-09 07:00","pubTimestamp":1791500422,"startTime":"0","endTime":"0","summary":"丨2026年10月9日星期五丨NO.1阿斯利康两款重磅ADC药物在华获批新适应证10月8日，阿斯利康宣布，由阿斯利康和第一三共联合开发和商业化的达卓优（通用名：注射用德达博妥单抗）于9月29日正式获得国家药监局批准，用于治疗不适合接受PD-1/PD-L1抑制剂治疗的不可切除或转移性三阴性乳腺癌成人患者。同日，阿斯利康还宣布，优赫得（通用名：注射用德曲妥珠单抗）也在中国获批。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610093890074039.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610093890074039.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2495084118.USD","LU2097828805.USD","MEDX","LNGR","LU2289578879.USD","BK1161","LU1064131003.USD","159938","01276","LU0405327148.USD","LU2097828474.EUR","LU2543165471.USD","LU0359201885.HKD","LU2097828557.USD","LU1655091616.SGD","BK0028","IBBQ","BK0188","06978","BK0060","BK1515","LU1146622755.USD","LU1580142542.USD","LU1997245177.USD","LU2097828714.EUR","09939","LU1997244956.HKD","LU1255011170.USD","LU1064130708.USD","BK1191","LU0359202008.SGD","BK0183","LU2328871848.SGD","BK0239","159992","600276","LU1781817850.SGD","LU2488822045.USD","LU1328615791.USD","IPOS","BK1574","LU0405327494.USD","LU1997245094.SGD","BK0012","LU1969619763.USD","LU2580892862.HKD","LU2580892789.USD","LU2097828631.EUR","LU0359201612.USD","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674007297","title":"XORTX概述了预计向加拿大卫生部提交的XRX-026治疗痛风临床试验申请。","url":"https://stock-news.laohu8.com/highlight/detail?id=2674007297","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674007297?lang=zh_cn&edition=fundamental","pubTime":"2026-10-09 04:00","pubTimestamp":1791489645,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["XRX","MDTX","BK4170","BMED","PSYK","IBBQ","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674004604","title":"三季报“窗口期”将至，机构看好AI、创新药等领域，投资者该如何关注？丨经济周刊·理财","url":"https://stock-news.laohu8.com/highlight/detail?id=2674004604","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674004604?lang=zh_cn&edition=fundamental","pubTime":"2026-10-09 00:08","pubTimestamp":1791475680,"startTime":"0","endTime":"0","summary":"长假后A股开盘首日，市场震荡调整，三大指数集体冲高回落，科创50指数低开低走。一方面是权重股银行股在震荡走强，另一方面是热门赛道CPO概念持续走弱，半导体产业链震荡调整。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://stock.eastmoney.com/news/1405,202610093890023621.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.eastmoney.com/news/1405,202610093890023621.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["BK1161","06978","QTOC","IBBQ","VTHR","BK1574","CHAT","MEDX","AGIX","ARTY","LNGR","AIPO","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673932003","title":"星巴克曾洽谈收购Chipotle 拟打造餐饮业重磅并购交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2673932003","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673932003?lang=zh_cn&edition=fundamental","pubTime":"2026-10-08 22:11","pubTimestamp":1791468660,"startTime":"0","endTime":"0","summary":"星巴克曾探讨收购Chipotle墨西哥烧烤餐厅，这项宏大交易计划意在合并美国两大知名消费品牌，若落地，将成为餐饮行业史上规模最大的并购案。目前尚无法确认星巴克收购计划的最新进展，以及该公司是否已向Chipotle提交正式收购要约。尼科尔2024年8月离开Chipotle之后，该公司股价近乎腰斩。星巴克拒绝置评，Chipotle暂未回应采访请求。尼科尔在Chipotle执掌超过六年。过去一年，Chipotle股价下跌近20%。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/world/2026-10-08/doc-iniuptat7485361.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IBBQ","XLFI","BK4209","BK4504","UYG","BK4588","IEFN","PBJ","ACTV","PEVC","MMID","BK4610","MNA","PRVT","CANC","VXF","IYH","SBUX","TBXU","RSPH","BK4585","BREW","DFMC","IE00B3T34201.USD","LU0882574139.USD","SBU","LU0823411888.USD","FFSM","RFG","PSP","AAUM","GTPE","BK4535","PBPH","EATZ","TMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673443008","title":"乐普医疗(300003.SZ)子公司MWN117注射液获得美国FDA药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2673443008","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673443008?lang=zh_cn&edition=fundamental","pubTime":"2026-10-08 21:49","pubTimestamp":1791467386,"startTime":"0","endTime":"0","summary":"智通财经APP讯，乐普医疗 发布公告，公司于今日获悉，公司控股子公司上海民为生物技术有限公司获得美国食品药品监督管理局关于同意MWN117注射液开展临床试验的通知书。MWN117注射液是上海民为生物自主研发的靶向抑制INHBE的siRNA药物，拥有全球知识产权，已于2026年8月获得CDE临床试验批准，适应症为超重或肥胖。同时，安全性评价试验显示MWN117注射液具有良好的安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1504909.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0042","BK0201","BK0251","BK0188","BK4588","BMED","300003","BK0028","BK4585","BK0196","MDTX","BK0114","BK0113","IBBQ","IBBJ","LABU","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673074940","title":"核心产品海外三期研究失败 艾力斯20cm跌停 还带崩了创新药板块？","url":"https://stock-news.laohu8.com/highlight/detail?id=2673074940","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673074940?lang=zh_cn&edition=fundamental","pubTime":"2026-10-08 19:59","pubTimestamp":1791460744,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","MEDX","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673741340","title":"核心产品海外三期研究失败 艾力斯20cm跌停 还带崩了创新药板块？","url":"https://stock-news.laohu8.com/highlight/detail?id=2673741340","media":"东方财富网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673741340?lang=zh_cn&edition=fundamental","pubTime":"2026-10-08 19:51","pubTimestamp":1791460260,"startTime":"0","endTime":"0","summary":"【核心产品海外三期研究失败 艾力斯20cm跌停 还带崩了创新药板块？】10月8日，A股多家药企股价下跌明显。具体来看，艾力斯20%跌停，丽珠集团10%跌停，亚虹医药跌超11%，益方生物、百奥泰、三生国健等跌超7%。业内普遍认为，此次创新药板块集体下挫的导火索是国内创新药企艾力斯的三期临床试验失败的负面消息。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://finance.eastmoney.com/news/1354,202610083889811123.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/news/1354,202610083889811123.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["688578","BK1574","MEDX","LNGR","BK0239","159992","06978","IBBQ","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673071276","title":"众生药业(002317.SZ)：一类创新药RAY1225注射液减重III期临床试验获得顶线分析数据结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2673071276","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673071276?lang=zh_cn&edition=fundamental","pubTime":"2026-10-08 19:35","pubTimestamp":1791459349,"startTime":"0","endTime":"0","summary":"智通财经APP讯，众生药业 发布公告，公司控股子公司广东众生睿创生物科技有限公司自主研发的一类创新多肽药物RAY1225注射液在超重或肥胖参与者的安全性和有效性的多中心、随机、双盲、安慰剂对照的III期临床试验，于近日获得顶线分析数据。REBUILDING-2临床试验于近日完成数据清理和锁定，获得顶线分析结果，达到主要终点。RAY1225注射液在主要有效性指标以及多种心血管和代谢危险因素改善等多个关键次要有效指标均显著优于安慰剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1504817.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","LNGR","BK0077","BMED","IBBQ","BK1161","06978","159992","BK1574","002317","BK0239","MDTX","IBBJ","PSYK","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673504076","title":"天坛生物(600161.SH)下属企业获得人凝血因子Ⅸ临床试验总结报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2673504076","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673504076?lang=zh_cn&edition=fundamental","pubTime":"2026-10-08 18:34","pubTimestamp":1791455673,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天坛生物(600161.SH)发布公告，近日，公司下属成都蓉生药业有限责任公司(简称“成都蓉生”)研制的“人凝血因子Ⅸ”完成了Ⅲ期临床试验并取得临床试验总结报告。据悉，成都蓉生生产的人凝血因子Ⅸ临床试验结果显示，该药物主要PK参数与同类已上市产品的数据相似，输注后能有效提升血友病B患者的凝血因子Ⅸ水平，提高血友病B患者的凝血功能，改善血友病B患者的出血症状和体征，可有效控制血友病B患者的出血。同时安全性结果显示，本品在临床应用过程中对血友病B患者具有良好的安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1504756.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0010","BK0082","IBBQ","BK0188","600161","PSYK","BK0046","BK0028","BK0185","IBBJ","MDTX","BK0239","BK0168","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673078792","title":"Truist上调安进目标价至380美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2673078792","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673078792?lang=zh_cn&edition=fundamental","pubTime":"2026-10-08 17:40","pubTimestamp":1791452438,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4588","BIB","LU2468319806.SGD","BK4534","AMGN","LU0122379950.USD","TBXU","LU0320765992.SGD","LU2089984988.USD","BK4581","BK4139","IE00BFTCPJ56.SGD","BK4566","BK4599","LU2242646821.SGD","LU2112291526.USD","LU0058720904.USD","BK4585","LU1057294990.SGD","BBH","LU1061106388.HKD","LU0889565916.HKD","LU0868494617.USD","IBBQ","IE00B4R5TH58.HKD","LU2242652126.USD","UDN","IE00BJT1NW94.SGD","PJP","IE00BJJMRZ35.SGD","LU1983299246.USD","LU0109394709.USD","PBE","IE00B2B36J28.USD","BK4533","IBB","IE0002141913.USD","LU0289739699.SGD","SG9999001440.SGD","LU1023059063.AUD","UUP","LU1571399168.USD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673208940","title":"天坛生物：成都蓉生人凝血因子Ⅸ获Ⅲ期临床试验总结报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2673208940","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673208940?lang=zh_cn&edition=fundamental","pubTime":"2026-10-08 17:01","pubTimestamp":1791450088,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","PSYK","IBBJ","MDTX","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673022144","title":"小摩上调吉利德科学目标价至170美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2673022144","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673022144?lang=zh_cn&edition=fundamental","pubTime":"2026-10-08 16:30","pubTimestamp":1791448219,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE0000B7K699.USD","LU0109394709.USD","UUP","LU0157215616.USD","TRUF","GILD","LU2237443549.SGD","LU2552382215.SGD","JPO","LU1145028129.USD","FNCL","LU0234572021.USD","LU2430703178.SGD","TFNS","LU0971096721.USD","IBB","BBH","BMED","IXG","VFH","JPMO","XLF","TBXU","FTXO","LU1548497426.USD","KBWB","IBBQ","IE000MB6IJN5.SGD","LU0965509283.SGD","LU1585245621.USD","LU2456880835.USD","LU1974910355.USD","IYG","IE0034235295.USD","LU1917777945.USD","LU0106831901.USD","LU1894683348.USD","UDN","UYG","LU0149725797.USD","LU0208291251.USD","LU0251132253.USD","TMED","MEDI","BIB","LU0320765489.SGD","IE00BJTD4N35.SGD","LU2237443382.USD","LU0256863902.USD","IYF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673022539","title":"翰宇药业：HY3003注射液临床试验申请获FDA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2673022539","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673022539?lang=zh_cn&edition=fundamental","pubTime":"2026-10-08 16:20","pubTimestamp":1791447617,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","BK4588","LABU","PSYK","IBBJ","MDTX","BK4585","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673024930","title":"核心产品海外关键Ⅲ期临床未达主要终点，400亿创新药企跌停","url":"https://stock-news.laohu8.com/highlight/detail?id=2673024930","media":"东方财富网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673024930?lang=zh_cn&edition=fundamental","pubTime":"2026-10-08 15:51","pubTimestamp":1791445875,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者韩利明10月8日，艾力斯（688578.SH）以92.83元/股开盘后20cm跌停，报89.26元/股，对应总市值401.67亿元。对比年内137.54元/股的高点，回撤达35.1%。利空源于一纸临床公告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://stock.eastmoney.com/news/11134,202610083889616077.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.eastmoney.com/news/11134,202610083889616077.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["06978","BK1161","LNGR","MEDX","159992","BK1574","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673269660","title":"韩国1至9月生物制药出口额创纪录，达66亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2673269660","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673269660?lang=zh_cn&edition=fundamental","pubTime":"2026-10-08 14:43","pubTimestamp":1791441821,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MRNX","BBP","IBBQ","MRNY"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}]}}